Cimetropium bromide, a new antispasmodic agent, has no hemolytic effects in humans.
Many agents have been reported to cause hemolytic anemia in glucose-6-phosphate dehydrogenase (G6PD) deficient subjects. We investigated whether cimetropium bromide, a new antispasmodic drug, can be safely given to these patients. In the first study, ten healthy volunteers were given 50 mg, p.o. 3 times per day, before meals for 1 week. Blood samples were drawn before and after treatment and stimulation of the hexose monophosphate shunt (HMS) was evaluated. No significant stimulation of HMS was observed. In a second study, 12 G6PD-deficient patients with spastic colon were given cimetropium bromide and placebo according to a double blind, cross-over design. None of the patients showed any significant abnormalities in any of the several hematologic parameters tested.
D000328:Adult; D005260:Female; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000097:blood; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D008297:Male; D010276:Parasympatholytics / Q000494:pharmacology*; D012602:Scopolamine Derivatives / Q000494:pharmacology*
D010276:Parasympatholytics; D012602:Scopolamine Derivatives; C016859:cimetropium